Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of ramosissimonea in preparation of medicine for treating rheumatoid arthritis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A rheumatoid and arthritis technology, applied in the application field of Ramosissimone A in the preparation of drugs for the treatment of rheumatoid arthritis, which can solve the problems of induced infection, poor action selectivity, damage, etc.
Active Publication Date: 2022-02-15
NINGXIA MEDICAL UNIV
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] At present, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) are mainly used for the treatment of rheumatoid arthritis, but these drugs all have obvious adverse reactions, such as the former damages the gastrointestinal tract tract mucosa leading to peptic ulcer, the latter has poor selectivity and is easy to induce infection, etc.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] Inhibitory effect of Ramosissimone A on proliferation of rheumatoid arthritis.
[0027] Cell: Human rheumatoid synovial cells (RA-FLS);
[0028] Drug: Ramosissimone A;
[0029] Method: 1. RA-FLS recovery
[0030] The RA-FLS freezing pipe is quickly removed from the liquid nitrogen irrigation, and the temperature of the temperature of 37 ° C is placed, and the cells are uninterrupted, and the cells are thawed. After being refined, the RA-FLS suspension in the frozen tube was moved to 10 ml of sterile centrifugal tube in the ultimate platform, centrifuged for 5 min, and the rotational speed was 1000R / min. Inverted the supernatant, add 5 ml of fully cultured liquid, continuously blowing to a homogeneous cell suspension with pipette, inoculation of RA-FLS in a 25 ml cell culture flask, placed in a cell incubator, and incubator conditions are set to Temperature 37 ° C, CO 2 The concentration is 5%. After 24 hours, the growth of RA-FLS was observed under the microscope, and whe...
Embodiment 2
[0039] Promoting effect of Ramosissimone A on apoptosis of rheumatoid arthritis.
[0040] Cell: Human rheumatoid synovial cells (RA-FLS);
[0041] Drug: Ramosissimone A;
[0042] Method: 1. RA-FLS recovery
[0043] Similarly to Example 1.
[0044] 2.RA-FLS pass
[0045] Similarly to Example 1.
[0046] 3.Tuneel method to determine apoptosis
[0047] The breakage of chromosome DNA in apoptosis is a progressive stage of step, and the chromosome DNA first degrades a large fragment of 50-300 kB in the endogenous nucleic acid hydrolase. Then approximately 30% chromosome DNA in CA 2+ And MG 2+ Under the dependent nucleic acid endozyme, the nucleic body unit is randomly cut, and 180 to 200 bp nucleom DNA polymer is formed. DNA Double-strand break or a series of DNAs generated by a gap in a chain can cause deoxyribonucleotides and fluorescene under the action of deoxyribonucleotide terminal transferase (TDT). The derivatives formed by peroxidase, alkaline phosphatase or biotin is labeled to...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to the application of a compound Ramosissimone A in the preparation of a medicine for treating rheumatoid arthritis. The present invention proves for the first time through pharmacological experiments that ramosissimone A has significant activity of inhibiting the proliferation of rheumatoid arthritis synoviocytes and inducing apoptosis of rheumatoid arthritis synoviocytes, and can be used to prepare drugs for preventing and / or treating rheumatoid arthritis, Therefore, it has high clinical application value and development prospect. The invention discloses the use of a compound ramosissimone A in the preparation of anti-rheumatoid arthritis drugs. The structural formula of Ramosissimone A is shown in formula I, and it is obtained by separating from branches of Tamarix multibranches. The present invention finds for the first time that ramosissimone A can significantly inhibit the proliferation of rheumatoid arthritis synoviocytes and induce the apoptosis of rheumatoid arthritis synoviocytes.
Description
Technical field [0001] The present invention relates to the application of Compound Ramosissimone A in the preparation of the treatment of rheumatoid arthritis drugs. Background technique [0002] Rheumatoid Arthritis, RA) is a chronic systemic autoimmune disease mainly based on joint lesions. At present, its pathogenesis is unclear. Clinical thinks of RA is mainly due to patient autoimmune dysfunction. , Causing allergic reactions, making anti-inflammatory cells detergeting, depositing in joint sites and making joint tissue deformity, disabling. According to the survey, the incidence of RA in the world is approximately 1-2%. The total number of RA patients in my country has exceeded 4 million, and the incidence is still a trend. [0003] At present, for rheumatoid arthritis mainly using non-steroidal anti-inflammatory drugs (double chlorine, aspirin, etc.) and immunosuppressive agents (6-mercaptogen, etc.), but these drugs have obvious adverse reactions, such as the former damag...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More